Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Last trade$4.63
Day change-$0.135 (-2.84%)
Day range$4.53 – $4.90
Volume379,780
Market cap$301M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$300.94M
Price / earnings
—
Price / book
2.26×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.82×
Profitability
Earnings per share
-$2.50
Return on assets
-83.3%
Return on equity
-118.5%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.19×
Current ratio
7.01×
Quick ratio
7.01×
Cash ratio
1.27×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$151.26M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KYTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$15.88M
$14.77M
$11.29M
$9.27M
$8.27M
$8.59M
$9.98M
$7.56M
Research and development
$27.02M
$24.79M
$30.07M
$30.01M
$30.46M
$35.82M
$37.43M
$33.48M
Total operating expenses
$42.9M
$39.56M
$41.37M
$39.28M
$38.73M
$44.41M
$47.41M
$41.04M
Operating income
-$42.9M
-$39.56M
-$41.37M
-$39.28M
-$38.73M
-$44.41M
-$47.41M
-$41.04M
Interest expense
-$728K
-$674K
-$667K
-$444K
-$7K
-$14K
-$25K
-$27K
Income before taxes
-$41.94M
-$38.32M
-$39.73M
-$37.8M
-$36.79M
-$42.08M
-$44.64M
-$37.49M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$41.94M
-$38.32M
-$39.73M
-$37.8M
-$36.79M
-$42.08M
-$44.64M
-$37.49M
Net income attributable to common shareholders
-$41.94M
-$38.32M
-$39.73M
-$37.8M
-$36.79M
-$42.08M
-$44.64M
-$37.49M
EBITDA
-$42.63M
-$39.12M
-$41.02M
-$38.91M
-$38.31M
-$43.9M
-$46.91M
-$40.48M
Basic earnings per share
-$0.68
-$0.63
-$0.66
-$0.80
-$0.85
-$0.97
-$1.03
-$0.87
Diluted earnings per share
-$0.68
-$0.63
-$0.66
-$0.80
-$0.85
-$0.97
-$1.03
-$0.87
Recent news
Company coverage with links to the original publishers.
Kyverna Therapeutics announced the publication of KYSA-8 registrational trial data for miv-cel in stiff person syndrome (SPS) in JAMA Neurology. The single-dose CAR T-cell therapy demonstrated statistically significant improvements across all primary and secondary endpoints at 16 weeks, with 67% of patients requiring walking aids at baseline no longer needing them. All patients discontinued chronic immunotherapies, and the therapy showed a well-tolerated safety profile with no high-grade adverse events.
The lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.
The article compares two biotech companies with contrasting profiles: Kyverna Therapeutics, a clinical-stage firm developing cell therapies for autoimmune diseases with no approved products and significant losses, versus Vertex Pharmaceuticals, an established leader generating $12 billion in revenue with a dominant cystic fibrosis franchise. The author recommends Vertex as the better 2026 investment due to its proven profitability, strong cash flow, and continued growth potential, while acknowledging Kyverna's high-risk, high-reward profile dependent on regulatory approval of its lead candidate.
Kyverna Therapeutics (KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases, announced upcoming presentations at the H.C. Wainwright 4th Annual Nasdaq BioConnect Conference on May 19th and the Jefferies Global Healthcare Conference on June 3rd, 2026. The company is advancing its lead CAR T-cell therapy candidate miv-cel across multiple B-cell-driven autoimmune indications, including stiff person syndrome and generalized myasthenia gravis.
Kyverna Therapeutics announced positive primary analysis results from its KYSA-8 registrational trial of miv-cel (mivocabtagene autoleucel) for stiff person syndrome (SPS). A single dose demonstrated statistically significant improvements across all primary and secondary endpoints at 16 weeks, with 81% of patients achieving clinically meaningful improvement in walking speed and all 26 patients discontinuing chronic immunotherapies. The company plans to submit a BLA for this indication and is advancing the therapy in generalized myasthenia gravis.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.